Singapore, December 6, 2023 – Update on the Detection of Existing Influenza A Variant
Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving influenza A virus detection to all sequences listed in NCBI Virus and GISAID up till December 4th, 2023.
We are pleased to announce that the VitaPCR™ system is capable of detecting the influenza A variant H1N2 and our analysis has confirmed that the performance of our influenza detection assays* is not impacted by the variant H1N2.
*The influenza detection assays include:
- VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
- VitaPCR™ Flu A&B Assay (PCRAE0103)
- VitaPCR™ Flu / RSV Assay (PCRAE0106)
For more information, contact us at service@credodxbiomed.com.
